Merck Highlights Exploratory Analysis Of KEYTRUDA Which Showed Improved Overall Survival As Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
Benzinga Newsdesk